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A B S T R A C T
Purpose: To evaluate and to compare the possible toxic effects of oxcarbazepine (OXC) and valproic acid
(VPA) on retinal ganglion cells (RGCs) in rat.
Methods: Forty femaleWistar rats (21–24 days old andweighted between 44.6 and 57.3 g) were divided
equally into 4 experimental groups whichwere applied tapwater (group 1), 300 mg/(kg day) VPA (group
2), 100 mg/(kg day) OXC (group 3), and both VPA and OXC (group 4) via gavage for 90 days. Enucleation
was performed for histopathologic analysis. RGCs were counted under the light microscopic
examination.
Results: RGC numbers in OXC and combined OXC-VPA groups were found to be lower than those of
control group. On the other hand RGC number was comparable with those of control group in VPA group.
Conclusion: OXC seems to be toxic to RGCs at 100 mg/kg dose when it is been given as a monotherapy or
combined with VPA. Single VPA treatment has no effect on RGC number.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsia is a neurologic disorder that may be associated with
visual alterations. There are various antiepileptic drugs that have
been used in the treatment of epilepsia. In patients with epilepsia,
visual disturbances may be caused by either the epilepsy itself or
by the anticonvulsant therapy which is being used to control
seizures. In recent years, visual side-effects have been studied in
epileptic patients treated with different antiepileptic drugs.
Valproate (VPA) is the one of these drugs that has been widely
used for the treatment of epilepsy and other neuropsychiatric
diseases such as bipolar disorders, migraine, and generalizedmood
disorders for nearly 40 years.1–3 VPA has been demonstrated to
cause deﬁcits in color vision after a short treatment period.4 On the
other hand, in other study, retinal nerve ﬁber layers in patients
with epilepsia were also analyzed clinically by using optical
coherence tomography (OCT) to ﬁnd out the mechanisms under-* Corresponding author at: Barıs¸ Sitesi, 59 sokak, No: 7, Eskis¸ehir Yolu – Ankara,
Turkey. Tel.: +90 312 284 7192; fax: +90 312 212 5794.
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1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.02.003lying this color-vision impairment.5 However, no signiﬁcant
differences were found between study groups.
Oxcarbazepine (OXC) is a newer antiepileptic agent that has
been used recently as a monotherapy or add-on treatment for
partial seizures, with or without secondarily generalized
seizures, and primary generalized tonic–clonic seizures.6 Its
use for childhood epilepsies has been increased recently.7 OXC
has been reported as a relatively safe antiepileptic drug, without
signiﬁcant visual impairment. On the other hand, it has also
been demonstrated to cause diplopia and blurred vision in
various studies although the underlying mechanism has not
been known.8
Histopathologic and anatomic changes in the eye secondary
to the VPA and OXC treatments have not been reported yet.
Visual symptoms secondary to the VPA and OXC therapy may be
the sign of optic nerve (ON) or retinal dysfunction. It has been
well-known that retinal ganglion cell (RGC) axons compose ON.
Furthermore, RGC loss secondary to the some toxic, ischaemic or
traumatic insults may cause clinically signiﬁcant ON dysfunc-
tion and color vision impairment. The aim of the current study
was to investigate the histopathologic changes in RGC layer
induced by direct toxic effects secondary to VPA and OXC
treatments.vier Ltd. All rights reserved.
Fig. 1. Light microscopic view of retina in group 1 (control), G: normal RGC layer,
IPL: normal inner plexiform layer, F: normal cell nuclei (Heamatoxylin-Eosine,
400).
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2.1. Animals
The 46 female Wistar rats (aged between 21 and 24 days old
and weighted between 44.6 and 57.3 g) from Gazi University
Medical Faculty Animal Laboratory were used in this experimental
study. All animals were housed in plastic cages at a constant room
temperature (21–22 8C) and in a 12 h light/12 h dark cycle (lights
on at 07:00 am). Rats were given free access to food and water. All
animal experiments were carried out in accordance with the
European Communities Council Directive of 24 November 1986
(86/609/EEC) andwere approved by the Animal Care Committee of
Gazi University.
2.2. Experimental procedure and dosing
Rats were divided into 4 experimental groups including 20
eyes of 10 rats in each group. Experimental groups were as
follows: group 1 (control group), that was applied control
solution, group 2 (VPA group), that was applied 300 mg/(kg day)
of VPA (Depakin1 200 mg/1000 mL solution, Sanoﬁ Dogu,
Istanbul, Turkey), group 3 (OXC group), that was applied
100 mg/(kg day) of OXC (Trileptal1 60 mg/1000 mL solution,
Novartis, Istanbul, Turkey), and group 4 (combined VPA-OXC
group), that was applied 300 mg/(kg day) VPA and 100 mg/
(kg day) OXC. Ordinary drinking water was used as the control
solution. Dosages of drugs in groups 2, 3 and 4 were deﬁned
according to the weights of rats. Rats were weighted weekly and
drug doses were adjusted accordingly. For example, a 100 g rat in
group 4 at ﬁfth week of the treatment received 30 mg VPA
according to the dose of 300 mg/(kg day) and 10 mg OXC
according to the dose of 100 mg/(kg day). For this purpose,
150 mL of the VPA solution with the concentration of 200 mg/
1000 mL and 170 mL of OXC solution with the concentration of
60 mg/1000 mL were applied. Control solution and antiepileptics
were administered orally for 90 days with 12 h intervals in two
divided doses via gavage prepared speciﬁcally by bending its tip of
metal tube and coating it with silicon.
VPA dose has been adopted from the study by Roste et al.9 In the
literature, the antiepileptic dose of OXC was proposed as 30 mg/kg
for single use and higher for chronic use.10 Cansu et al.11 also used
the higher dose of 100 mg/(kg day) in their study.
2.3. Histopathologic analysis and RCG count
All tissues were transferred immediately to 10% formal saline
for 72 h, dehydrated in graded alcohols and embedded in parafﬁn
wax. 4 mm sections were cut on a microtome (Leica SM 2000,
Germany). Afterwards, the slides were counterstained with
heamatoxylin-eosine. Images were taken of each section using
a Leica DM 4000B (Leica, Weetlar, Germany) photomicroscope
and a Leica DFC280 plus camera. The number of the RGCs is
measured manually by using Qwin (V3 Plus image) software
program in consecutive areas for serial cutaways taken from each
subject.12,13 Morphologic alterations in RGC layer were also
evaluated under the light microscopic examination in a masked
fashion.
2.4. Statistical analysis
RGC numbers in groups 2, 3 and 4 compared with group
1 (control) by using Mann–Whitney U test. SPSS version 11.0
system for personal computer was used and p < 0.05
was regarded as statistically signiﬁcant for all statistical
analyses.3. Theory
Theory of the current study was that VPA and OXC, popular
antiepileptic drugs, might have caused direct toxic effects in RGC
layer based on the fact that they affect visual function.
4. Results
4.1. RGC count
Mean RGC number in group 1 (control) was 16.4  5.3 (9–28). In
group 2 (VPA), RGC numberwas 14.0  3.1 (10–22) and the difference
between groups 1 and 2 was not found to be statistically signiﬁcant
(p: 0.128). On the other hand, RGC numbers in group 3 (OXC) and
group 4 (combined OXC-VPA) were 12.5  2.7 (8–18) and 10.0  1.9
(6–14). RGC numbers in both groups 3 and 4 were found to be
signiﬁcantly lower than that of group 1 (p: 0.012 and p: 0.001,
respectively).
4.2. Histopathologic examination
In histopathologic examination, there was a classical appear-
ance of RGC layer composed of healthy and homogenous RGCs in
group 1 (control; Fig. 1). RGC atrophy with a decrease in thickness
of the RGC layer was observed in group 2 (VPA) whereas the
anatomy of the RGC layer was relatively to be well-preserved
(Fig. 2). In group 3 (OXC), there was a signiﬁcant anatomic and
organizational disruption in RGC layer together with RGC atrophy
(Fig. 3). The most prominent histopathologic ﬁnding encountered
in group 3 was intrastoplasmic edema. Furthermore, the other
signiﬁcant histopathologic ﬁnding was nuclear shrinkage of the
RGCs. Decreased thickness together with cell loss in RGC layer was
also signiﬁcant in group 3. In group 4 (combined OXC-VPA), there
was a signiﬁcant disruption of RGC layer anatomy together with
severe RGC loss and atrophy leading to decreased thickness of RGC
layer compared with that of group 1 (Fig. 4).
5. Discussion
In the current study, we investigated the morphologic
alterations caused by VPA and OXC treatments, in the RGC layer
of rat. We found that OXC treatment caused signiﬁcant negative
effects on the structure and number of the RGCs whereas VPA
treatment led only RGC atrophy without causing signiﬁcant RGC
loss.
Fig. 2. (A and B) Light microscopic view of retina in group 2 (VPA), G: atrophic RGC layer, IPL: normal inner plexiform layer,!: intracytoplasmic edema, F: normal cell nuclei,
^: separation between cells of RGC layer (Heamatoxylin-Eosine, 400).
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epilepsy. VPA is a broad-spectrum antiepileptic drug that has been
used as a ﬁrst-line agent for both the treatment of generalized and
partial seizures. Sorri et al.14 investigated whether initial VPA
monotherapy for the treatment of epilepsy causes visual ﬁeld
defects or other visual dysfunction. They found no visual ﬁeld
defect secondary to the VPA treatment but they demonstrated VPA
induced abnormalities in color vision. Some other studies in the
current literature also support that epilepsy patients treated with
VPAmonotherapy develop disturbances in color vision even after a
short treatment period.4,15 These effects on color vision might be
resulted from changes at the level of the retinal processing or
anatomy.
OXC, is a new generation antiepileptic drug and a keto analog of
carbamazepine.16 It has been widely used for the treatment of
partial and secondary generalized tonic–clonic seizures with a
better tolerability proﬁle. Although it has mainly marketed as an
alternative to carbamazepine, there is no reported association
between the OXC treatment and wide variety of visual dis-
turbances like carbamazepine.17 Themost common ocular adverse
effects associated with OXC are diplopia and blurred vision.8 It has
also been found that OXC caused subtle visual alterations together
with saccadic and smooth-pursuit eye movements.18Fig. 3. Light microscopic view of retina in group 3 (OXC), G: degenerated RGC layer,
IPL: normal inner plexiform layer !: intracytoplasmic edema, F: shrinked nuclei
(Heamatoxylin-Eosine, 400).To the best of our knowledge, there is no animal or
postmortem study in the literature investigated the underlying
changes or mechanisms of these visual disturbances encoun-
tered secondary to these agents used for the treatment of
epilepsia. There is only one clinical study investigating the
relationship between ocular symptoms and retinal anatomy by
using OCT.5 OCT is a useful clinical tool that can measure the
thickness of retinal nerve ﬁber layer and macula. It can be used
to support the diagnosis of various ocular diseases affecting the
structure of retina and optic nerve such as glaucoma or age
related macular degeneration. Structural alterations have been
known to precede the development of visual ﬁeld defects and
clinical symptoms in these types of patients. Thus, OCT makes
clinician evaluate the correlation between these structural
changes and patient’s visual symptoms. Lobefalo et al.5 demon-
strated that epilepsy patients did not have any alteration in
retinal nerve ﬁber layer and macular thickness after 1 year of
treatment with VPA and CBZ by using OCT and there was no
structural alteration even in the presence of color-vision defects.
However, in this study, there was no data including RGC layer of
these patients since it is not possible to evaluate RGC layer with
this device. Color-vision and visual ﬁeld defects could be a sign
of retinal toxicity or optic neuropathies such as glaucomaFig. 4. Light microscopic view of retina in group 4 (combined VPA-OXC), G: RGC
layer composed of degenerated and atrophied cells, IPL: inner plexiform layer, F:
decreased number of RGC nuclei (Heamatoxylin-Eosine, 400).
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decreased macular thickness and optic nerve excavation.19,20
Macular thickness, retinal layers and changes in optic nerve
parameters caused by various ocular diseases are widely
evaluated clinically in ophthalmology practice, since these
parameters are signiﬁcantly important for the preservation of
visual function. Loss or disruption of RGCs can also affect all of
these parameters.
RGCs are also known to be involved in color vision and there are
nearly 1millionRGCs in the eye. Information coming from the retina
is carried to higher centers through the axons of RGCs. Retina has a
complex structure includingRGCs thatmakeconnectionswithother
cells. Basically, in front of the rods and cones that are located at the
back of the retina, there are other types of cells: bipolar cells,
horizontal cells and amacrine cells. Retinal processing begins at the
output terminal of the cone, cone pedicle and continues through the
complex pathways including bipolar cells, horizontal cells amacrine
cells and RGCs. The RGCs add and subtract signals coming from
many cones.21 The result of these steps is a signal that is sent to the
brain for color vision. So, any insult leading to RGC damage might
also cause defective color vision.
Consequently, color vision loss and visual disturbances both
may be resulted from chronic RGC loss. It may also be associated
with photoreceptor loss as described above. On the other hand, we
only investigate the toxic effects on RGCs secondary to OXC and
VPA treatments. Loss and disruption of RGCs caused by these
antiepileptic drugs may contribute to their side-effects on visual
function. However, their effects on photoreceptors may be
investigated in further studies.
Color vision and visual ﬁeld defects might be secondary to the
various optic neuropathies. As far as we know, chronic ocular
diseases leading to chronic loss of RGCs such as glaucoma or
ischaemic retinal diseases can cause further ON damage and
secondary visual disturbances. In other words, chronic disruption
of RGC layer has been known to be associated with ON
dysfunction similar to those seen with glaucoma or ischaemic
optic neuropathy. Toxic insults may also affect RGC layer and ON.
Histopathologic mechanisms underlying the color vision defects
and visual disturbances in these patients have not been known.
These possible histopathologic alterations that have not been
detected clinically precede the development of clinical symp-
toms. Duration of the treatment and the dose of the antiepileptic
drug may possibly affect the degree of the toxicity or the severity
of the clinical symptoms.As a new generation antiepileptic drug,
exact place of OXC in the treatment of epilepsia especially in
young patients is not clear. Since the fact that it is being relatively
free of side effects compared with other antiepileptic drugs, OXC
may be thought as a more advantageous treatment option. In this
study, we have investigated whether two of the most common
antiepileptic drugs, VPA and OXC cause any toxic effects in RGC
layer of rat retina. OXC was given with the dose of 100 mg/kg for
90 days that was suggested for its chronic use.9 We found that
OXC caused signiﬁcant RGC toxicity when it is used in this chonic
dose scheme. It caused signiﬁcant RGC loss and atrophy when it
was given as a monotherapy or together with VPA. However,
although we used VPA in 300 mg/kg dose, only RGC atrophy was
found without signiﬁcant loss compared with that of OXC
treatment.
On the other hand, one of the main drawbacks of our
experimental study is the difﬁculty of the application of these
results to human, clinically. The other factor is the doses that was
used. Half-life of these drugs may be different in rats compared
with those of human. However, it is also difﬁcult to ﬁnd an acute
and chronic doses of antiepileptic drugs exactly in rats compared
to human. Thus, the toxic effects that we demonstrated in the
current study might also be resulted from the doses that was used.6. Conclusions
To thebest of our knowledge, therehas beennoknowledge about
the histopathologic alterations underlying the ocular side effects of
OXC and VPA. Chronic loss of RGCs may lead to serious optic
neuropathy causing visual disturbance in long term. However, this
should be kept in mind that even OXC, a new generation
antiepileptic drug with a fewer ocular side effect proﬁle, might
cause a signiﬁcant toxic RGC loss. Thus, further histopathologic or
clinical studies are needed to demonstrate the exact relationship
between the RGC loss and OXC or VPA treatments in human.
Different doses of OXC and VPA should also be used to ﬁnd safe,
nontoxic and also effective dose in these future clinical studies. The
results of our studymayprovide an important basis for these further
studies. Consequently, if they are toxic to RGCs in human, some
neuroprotective treatmentsmaybeneeded to increase RGC survival
in patients treated with OXC or VPA therapies.
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